March 8, 2018

CRISPR-Based System Identifies Important New Drug Targets in a Deadly Leukemia-Cold Spring Harbor Laboratory

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The renegade molecule, MEF2C, […]
March 7, 2018

New Therapies for Acute Leukemia

While 2017 was a milestone year for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), where a combined 7 agents were approved by the FDA, […]
March 6, 2018

Epigenetics therapy shows promise in patients with lymphoma

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to new data from the European Society for Medical Oncology
January 26, 2018

Venetoclax Active in CLL Progressing After Idelalisib

Venetoclax had promising clinical activity, with a high objective response rate among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with idelalisib, according […]
January 23, 2018

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients

 It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T-cell approach that is less toxic and does not require […]
January 1, 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Phase 3 results from the ECHELON-1 study, presented at the 59th Annual Meeting & Exposition of the American Society of Hematology, showed superior modified progression-free survival […]
December 19, 2017

Copanlisib May Benefit Patients with Relapsed or Refractory Indolent B-cell Lymphoma

Updated analyses are validating the efficacy of copanlisib in the treatment of relapsed or refractory indolent B-cell lymphoma. Investigators reported at the 2017 annual meeting of […]
December 11, 2017

Selinexor Plus Sorafenib May Benefit Patients with Relapsed/Refractory FLT3-Mutated AML

The combination of selinexor and sorafenib appears to be safe with clinical activity and apoptosis induction in patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia […]
December 5, 2017

New Drug Target Discovered for Acute Myeloid Leukemia

 A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells 
November 13, 2017

Responses Better With Bosutinib vs Imatinib in Untreated CML

Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the […]
August 18, 2017

FDA Approves New Acute Lymphoblastic Leukemia Treatment

The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]